Let Your Immune System
Treat Your Cancer

Denvax Success Stories

• NON HODGKINS LYMPHOMA

  A 46-year-old male was operated for mediastinal tumor in 2010. It was diagnosed as T-cell lymphoma (Lymphoblastic Lymphoma). He started his treatment with chemotherapy. Each time he had to be admitted for managing the complications of chemotherapy. He was losing weight and appetite and having erosions of mucosal membrane. He required G-CSF injections along with antibiotics and lots of IV fluids to maintain his cell counts and nutrition. He was unable to tolerate 4th dose of chemotherapy when he consulted his oncologist to combine chemotherapy with dendritic cell therapy. During the course of conventional treatment, he received mediastinal radiation also for 4 weeks.  The oncologist accepted the protocol and the chemotherapy was combined with DENVAX cell therapy doses that concluded in six months (from November 2010 to April 2011).  

  With this combined approach he stopped developing the post-chemotherapy complication. The patient suffered no chemo-related adverse effects contrary to the earlier findings. He has improved in performance status and is working in his office without taking a day-off from work. He is having regular follow ups and is free of disease as confirmed by his PET-CT in January 2011.

• PANCREATIC CANCER TREATMENT

  Ms. ArunaTyagi, a 44-year-old patient of cholangiocarcinoma (gallbladder duct) treated by Dr. Jamal A. Khan by dendritic cell therapy, is cancer-free for the last five years. Ms. Tyagi had primary cancer in common bile duct, pancreas and duodenum. She was operated upon by Whipple's procedure in May 2006 and completed her chemotherapy and radiation, but the success was short lived. After 9 months she developed a swelling in abdominal wall (secondary metastsis). The surgeon took a second chance and she was again operated for abdominal metastasis. She was offered second line chemotherapy by her treating physician but she refused knowing it would not give her long term benefits. She came to know of Dr. Jamal A. Khan, cancer immunotherapist, pioneer of Dendritic cell therapy in India. Dr. Khan MBBS, MD who has treated over a thousand patients till date, discussed the cancer treatment plan with her. He put her on low-dose gemcitabine chemotherapy along with DENVAX -dendritic cell therapy. She received three doses of gemcitabine and three doses of DENVAX dendritic cell therapy in the initial two months’ period and later on kept on DENVAX-monthly therapy. She was constantly monitored by serum marker tests and ultrasound exams. Gradually, the DENVAX therapy was given at increasing intervals. In August 2009, she was subjected to PET-CT examination and found to be completely free of disease with no active lesions found. 
  
  She continues to receive Denvax Therapy from Dr. Jamal A. Khan and is cancer-free, till date.

  Disclaimer: It is the OTPL’s policy never to disclose patient identity. This is an isolated case where we are disclosing the patient's identity. This information is shared in consent with Mrs. ArunaTyagi. It has also been covered in the magazine 'The Week' published from India dated 11 August, 2012.

• RENAL CANCER

  A 60-year-old female presented with metastatic clear cell carcinoma of kidney in December 2007. Her right kidney was excised and subjected to histopathology examination. It revealed pathological stage TNM- pT3 N1 M1. Her complaints were pain in abdomen and frequent urination. She presented with weight loss and anemia.
  She was given the option of DENVAX, dendritic cell-based immunotherapy. She received five doses at monthly interval. In three doses, her complaints began to resolve and was back to her normal self in five doses. Intermittently, she continued to receive DENVAX therapy.

  She was again evaluated in March 2011 for routine check up and was further advised to received additional DC therapies. Her reports indicate no active disease. Overall her health is good and she does all her normal activities without any assistance.

  She is completing 4 years of her quality life without receiving chemotherapy, monoclonal antibodies or interferons and is maintained on dendritic cell therapy.

• CANCER URINARY BLADDER

  An elderly male suffering from cancer of the urinary bladder (Transitional Cell Carcinoma) received Denvax therapy. He developed the disease in 2012 that was surgically removed. Post-surgery he opted for Denvax therapy. The referral came from his daughter who is a leading pathologist in Mumbai. During the first three months of therapy he additionally received BCG infusions into the urinary bladder given by his surgeon. Unfortunately, the disease relapsed in four months and he had to undergo second surgery to clear off the lesion. They were now having options to take chemotherapy although expected success was very little. The surgeon asked them to consider taking out urinary bladder completely but patient refused due to the poor quality of life he would lead. We suggested considering exclusive Dendritic cell therapy as BCG had failed to check the disease before moving to next step. It is known that the BCG treatment creates inflammatory response and serves as bait for immune cells to come and take control of cancer cells. The inflammatory response probably disturbed the T-cell based protection that we were going to get with Dendritic cells. The patient agreed and we gave him another set of six doses of Denvax. He was re-examined and no new growth of tumor was detected. He continues to receive Denvax at three-months interval. It is almost three years of disease-free period now. He plays golf five days-a week and drives his car at the age of 76 years.

• LIVER CANCER

  A young female consulted me in late 2014. She had a history of HCC (Hepatocellular carcinoma) with Hepatitis B positive status, with resection performed in early 2014. Gradually she progressed with disease. When she came to our clinic she had weakness and lethargy. Her PET-CT indicated disease in the liver and lungs. Her lab parameters were deranged but serum bilirubin was within normal limits. She was put on Denvax, dendritic cell therapy, and within three months of therapy she started showing signs of improvement. Her latest PET-CT done this month has shown complete resolution of the disease. Additionally, her hepatitis B test has become negative. Nothing of this sort has ever been reported in the medical literature.

• KIDNEY CANCER

  A dynamic, middle-aged male diagnosed of metastatic RCC (Renal cell carcinoma) and operated in 2012, developed widespread metastasis by 2013. He was treated in one of the leading hospitals in Gurgaon. He was taking monoclonal antibody (mab) designed for RCC but to no avail. He consulted and opted for additional (adjuvant) Dendritic cell therapy. We gave him the first dose in January 2014. The mab was gradually reduced to half and subsequently to quarter of the standard dose. He started gaining weight and cleared off of all his lesions in the body. His PET CT indicated complete resolution of the disease. He is on dendritic cell therapy maintenance therapy at monthly intervals. He travels widely not only between cities but countries due to his professional commitments. He can afford that as his health is perfectly normal and has no complaints of whatsoever type he used to have earlier.  His lab parameters are also normal. He is evaluated in August 2015

• OVARIAN CANCER TREATMENT

  A 58-year-old lady was diagnosed of cancer ovary in June 2004. Her CA 125 antigen marker was positive and in the range of 10,000 units. She was operated upon and given six cycles of chemotherapy. She recovered from her disease and her marker was also within normal range.  After one year, the CA 125 began rising and she presented to us with an increased titre of 400 units. There were signs of recurrence, and she opted for DC (DENVAX) therapy in June 2005. She has completed three years of receiving DENVAX. She is free of disease, proven both clinically and by radiological examinations. Her CA 125 marker is also stable for the last three years.We have done series of ovarian cancer patients and the presentation is available in publications section of our webpages.